JIA
MCID: JVN010
MIFTS: 72

Juvenile Rheumatoid Arthritis (JIA)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Juvenile Rheumatoid Arthritis

MalaCards integrated aliases for Juvenile Rheumatoid Arthritis:

Name: Juvenile Rheumatoid Arthritis 12 76 53 25 6 15 73
Juvenile Idiopathic Arthritis 12 53 25 37 15
Juvenile Arthritis 53 43 73
Monarticular Juvenile Rheumatoid Arthritis 12 73
Systemic Juvenile Rheumatoid Arthritis 12 25
Juvenile Chronic Polyarthritis 12 73
Arthritis, Juvenile Rheumatoid 53 25
Juvenile Chronic Arthritis 53 25
Acute Polyarticular Juvenile Rheumatoid Arthritis 73
Pauciarticular Onset Juvenile Chronic Arthritis 12
Pauciarticular Juvenile Rheumatoid Arthritis 73
Rheumatoid Arthritis, Systemic Juvenile 73
Acute Juvenile Rheumatoid Arthritis 12
Pauciarticular Juvenile Arthritis 12
Arthritis Juvenile Rheumatoid 55
Juvenile Ra 25
Jia 25
Jra 25

Classifications:



Summaries for Juvenile Rheumatoid Arthritis

MedlinePlus : 43 Juvenile arthritis (JA) is arthritis that happens in children. It causes joint swelling, pain, stiffness, and loss of motion. It can affect any joint, but is more common in the knees, hands, and feet. In some cases it can affect internal organs as well. The most common type of JA that children get is juvenile idiopathic arthritis. There are several other forms of arthritis affecting children. One early sign of JA may be limping in the morning. Symptoms can come and go. Some children have just one or two flare-ups. Others have symptoms that never go away. JA can cause growth problems and eye inflammation in some children. No one knows exactly what causes JA. Most types are autoimmune disorders. This means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. JA can be hard to diagnose. Your health care provider may do a physical exam, lab tests, and x-rays. A team of providers usually treats JA. Medicines and physical therapy can help maintain movement and reduce swelling and pain. They may also help prevent and treat complications. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Juvenile Rheumatoid Arthritis, also known as juvenile idiopathic arthritis, is related to rheumatoid factor-negative juvenile idiopathic arthritis and oligoarticular juvenile idiopathic arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Juvenile Rheumatoid Arthritis is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Methotrexate and Leflunomide have been mentioned in the context of this disorder. Affiliated tissues include joint, bone and testes, and related phenotypes are joint dislocation and arthritis

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

Genetics Home Reference : 25 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints.

NIH Rare Diseases : 53 Juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. When the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. Some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. Like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors. To be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. Diagnosis of the condition may be based on blood tests, X-rays, and ruling out other similar conditions. Treatment options may include medications and  physical therapy.

Wikipedia : 76 Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis, is the most common... more...

Related Diseases for Juvenile Rheumatoid Arthritis

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Juvenile Rheumatoid Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)
# Related Disease Score Top Affiliating Genes
1 rheumatoid factor-negative juvenile idiopathic arthritis 33.8 HLA-DRB1 IL2RA SLC11A1
2 oligoarticular juvenile idiopathic arthritis 33.6 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA TNF
3 systemic onset juvenile idiopathic arthritis 33.1 IL1RN TNF
4 rheumatoid arthritis, systemic juvenile 32.9 HLA-DRB1 IL1R1 IL6
5 adult-onset still's disease 31.2 CRP IL18 IL1B IL1R1 IL1RN IL6
6 uveitis 31.1 IL1R1 IL2RA TNF
7 arthritis 31.1 HLA-DRB1 IL18 IL1B IL1RN IL6 LTA
8 spondyloarthropathy 1 30.6 CRP TNF TNFRSF1B
9 bronchiolitis 30.5 CRP IL6 TNF
10 anterior uveitis 30.5 IL2RA IL6 TNF
11 vasculitis 30.5 CRP S100A9 TNF TNFRSF1B
12 rubella 30.5 HLA-DPB1 HLA-DRB1 TNF
13 granulomatous dermatitis 30.4 TNF TNFRSF1B
14 mumps 30.2 HLA-DPB1 HLA-DRB1 IL2RA TNF
15 panuveitis 30.2 HLA-DRB1 TNF TNFRSF1B
16 purpura 30.1 CRP IL6 TNF
17 spondylitis 30.1 CRP IL1RN IL6 LTA TNF TNFRSF1B
18 familial mediterranean fever 30.0 CRP IL1B IL1RN TNF
19 periodontitis 30.0 BGLAP CRP IL1B IL6 TNF
20 connective tissue disease 30.0 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL6 TNF
21 acute pancreatitis 29.9 CRP IL18 IL6
22 pustulosis of palm and sole 29.9 IL1RN TNF TNFRSF1B
23 pneumonia 29.9 CRP IL1B IL6 TNF
24 optic neuritis 29.9 HLA-DRB1 LTA TNF
25 lyme disease 29.9 CRP IL1B IL6 TNF
26 osteomyelitis 29.9 IL1B IL1RN IL6 TNF
27 rheumatic fever 29.9 HLA-DQA1 HLA-DRB1 IL6 TNF
28 juvenile ankylosing spondylitis 29.9 IL1RN IL6 TNF TNFRSF1B
29 chronic fatigue syndrome 29.8 IL1B IL6 TNF
30 kawasaki disease 29.8 CRP IL6 S100A12 TNF
31 rheumatoid arthritis 29.8 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B
32 aggressive periodontitis 29.8 IL1B IL1RN IL6 TNF
33 crohn's disease 29.7 CRP S100A12 S100A9 SLC11A1 TNF
34 keratoconjunctivitis sicca 29.7 IL1B IL6 TNF
35 meningitis 29.7 CRP IL1B IL6 TNF
36 cerebral palsy 29.7 IL1B IL6 LTA TNF
37 gastroenteritis 29.6 CRP IL1B IL6 TNF
38 sleep apnea 29.6 CRP IL1B IL6 TNF
39 peritonitis 29.6 CRP IL1B IL6 TNF
40 tonsillitis 29.6 IL1B IL6 LTA TNF
41 takayasu arteritis 29.6 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL6 TNF
42 aseptic meningitis 29.6 IL1B IL1R1 IL1RN TNF
43 palindromic rheumatism 29.5 CRP HLA-DRB1 IL1B TNF TNFRSF1B
44 colitis 29.5 IL1B IL6 S100A12 TNF
45 pericarditis 29.5 CRP IL1B IL1RN IL6 TNF
46 joint disorders 29.5 IL1B IL1R1 IL1RN IL6 TNF
47 psoriatic arthritis 29.4 CRP HLA-DRB1 IL1B IL6 LTA S100A12
48 multiple sclerosis 29.4 HLA-DRB1 IL1B IL2RA IL6 LTA TNF
49 osteoporosis 29.3 BGLAP CRP IL1B IL1RN IL6 TNF
50 synovitis 29.1 CRP IL18 IL1B IL1RN IL6 TNF

Graphical network of the top 20 diseases related to Juvenile Rheumatoid Arthritis:



Diseases related to Juvenile Rheumatoid Arthritis

Symptoms & Phenotypes for Juvenile Rheumatoid Arthritis

Human phenotypes related to Juvenile Rheumatoid Arthritis:

32 (show all 22)
# Description HPO Frequency HPO Source Accession
1 joint dislocation 32 frequent (33%) HP:0001373
2 arthritis 32 hallmark (90%) HP:0001369
3 splenomegaly 32 occasional (7.5%) HP:0001744
4 hepatomegaly 32 occasional (7.5%) HP:0002240
5 joint stiffness 32 frequent (33%) HP:0001387
6 malabsorption 32 frequent (33%) HP:0002024
7 fever 32 hallmark (90%) HP:0001945
8 joint swelling 32 frequent (33%) HP:0001386
9 arthralgia 32 hallmark (90%) HP:0002829
10 generalized hyperkeratosis 32 frequent (33%) HP:0005595
11 abdominal pain 32 frequent (33%) HP:0002027
12 abnormality of the pleura 32 frequent (33%) HP:0002103
13 abnormality of the fingernails 32 frequent (33%) HP:0001231
14 autoimmunity 32 hallmark (90%) HP:0002960
15 skin rash 32 frequent (33%) HP:0000988
16 mediastinal lymphadenopathy 32 frequent (33%) HP:0100721
17 nail pits 32 frequent (33%) HP:0001803
18 uveitis 32 frequent (33%) HP:0000554
19 cartilage destruction 32 frequent (33%) HP:0100773
20 abnormality of the sacroiliac joint 32 frequent (33%) HP:0100781
21 pericardial effusion 32 occasional (7.5%) HP:0001698
22 psoriasiform dermatitis 32 frequent (33%) HP:0003765

UMLS symptoms related to Juvenile Rheumatoid Arthritis:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 9.02 BGLAP HAPLN1 HLA-DPB1 IL1RN SLC11A1

MGI Mouse Phenotypes related to Juvenile Rheumatoid Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 HAPLN1 HLA-DQA1 IL18 IL1B IL1R1 IL1RN
2 homeostasis/metabolism MP:0005376 10.03 CRP DEK IL18 IL1B IL1R1 IL1RN
3 cardiovascular system MP:0005385 10.02 CRP IL18 IL1B IL1R1 IL1RN IL6
4 immune system MP:0005387 9.97 CRP HLA-DQA1 IL18 IL1B IL1R1 IL1RN
5 mortality/aging MP:0010768 9.73 HAPLN1 IL18 IL1B IL1R1 IL1RN IL2RA
6 neoplasm MP:0002006 9.17 DEK IL1B IL1R1 IL6 SLC11A1 TNF

Drugs & Therapeutics for Juvenile Rheumatoid Arthritis

Drugs for Juvenile Rheumatoid Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 59-05-2, 1959-05-2 126941
2
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 185243-69-0
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
6
leucovorin Approved Phase 4,Phase 3,Early Phase 1 58-05-9 6006 143
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
10
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
13
Famotidine Approved Phase 4 76824-35-6 3325
14
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1 22204-53-1 1302 156391
15
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
17
Sulfasalazine Approved Phase 4,Phase 3 599-79-1 5353980 5359476
18
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
19
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Early Phase 1 59-30-3 6037
21
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Vaccines Phase 4,Phase 3,Not Applicable
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
33 Autonomic Agents Phase 4,Not Applicable
34 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
35 Antimetabolites Phase 4,Phase 3,Early Phase 1
36 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Early Phase 1
37 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Folic Acid Antagonists Phase 4,Phase 3,Early Phase 1
41 Vitamin B9 Phase 4,Phase 3,Early Phase 1
42 Vitamin B Complex Phase 4,Phase 3,Early Phase 1
43 Prednisolone acetate Phase 4,Phase 3,Not Applicable
44 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Folate Phase 4,Phase 3,Early Phase 1
47 Protective Agents Phase 4,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
49 Antiemetics Phase 4,Not Applicable
50 Neuroprotective Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
2 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer Unknown status NCT01845922 Phase 4
5 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
6 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
7 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
8 A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
9 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
10 A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Completed NCT00807846 Phase 4 Celecoxib;Naproxen
11 Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA Completed NCT00792233 Phase 4
12 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
13 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
14 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
15 A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
16 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
17 A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) Active, not recruiting NCT01734382 Phase 4 Tocilizumab
18 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
19 Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
20 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
21 Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
22 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
23 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA) Completed NCT03780959 Phase 2, Phase 3 Etanercept;Placebo
24 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3 Infliximab
25 Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA Completed NCT00570934 Phase 3 Placebo
26 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
27 Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
28 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
29 Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan Completed NCT01835470 Phase 3 Abatacept
30 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Completed NCT00775437 Phase 3 Adalimumab
31 An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
32 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis Completed NCT01541917 Phase 3
33 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
34 Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
35 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
36 An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. Completed NCT00891046 Phase 3 Canakinumab
37 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
38 Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS Completed NCT00339157 Phase 2, Phase 3 Anakinra
39 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
40 Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis Completed NCT00420251 Phase 3 Genotropin
41 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
42 Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT00889863 Phase 3 canakinumab;placebo
43 A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies Completed NCT02334748 Phase 3 canakinumab
44 Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA Completed NCT02396212 Phase 3
45 Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis Completed NCT00962741 Phase 3 Etanercept
46 A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
47 Comparison of Two Different Methods of Delivering Local Analgesia During Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis Completed NCT00465504 Phase 3
48 ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
49 Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
50 Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed NCT00144664 Phase 3 MRA(Tocilizumab)

Search NIH Clinical Center for Juvenile Rheumatoid Arthritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Juvenile Rheumatoid Arthritis

Anatomical Context for Juvenile Rheumatoid Arthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Juvenile Rheumatoid Arthritis:

19
Joint

MalaCards organs/tissues related to Juvenile Rheumatoid Arthritis:

41
Bone, Testes, T Cells, Skin, Eye, Liver, Neutrophil

Publications for Juvenile Rheumatoid Arthritis

Articles related to Juvenile Rheumatoid Arthritis:

(show top 50) (show all 1940)
# Title Authors Year
1
Effects of Structured Exercise Training in Children and Adolescents With Juvenile Idiopathic Arthritis. ( 30557274 )
2019
2
Commentary on "Effects of Structured Exercise Training in Individuals With Juvenile Idiopathic Arthritis". ( 30557275 )
2019
3
Self-rated walking disability and dynamic ankle joint stiffness in children and adolescents with Juvenile Idiopathic Arthritis receiving intraarticular corticosteroid joint injections of the foot. ( 30396058 )
2019
4
Simultaneous Quadruple Joint Replacement (QJR) in Disabling Juvenile Rheumatoid Arthritis - a Case Report with Review of Literature. ( 29911143 )
2018
5
Levels of Health Theory With the Example of a Case of Juvenile Rheumatoid Arthritis. ( 29896977 )
2018
6
Difficulty in the diagnosis of bone and joint pain associated with pediatric acute leukemia; comparison with juvenile idiopathic arthritis. ( 28612674 )
2018
7
Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. ( 30527427 )
2018
8
Correlation of temporomandibular joint clinical signs with cone beam computed tomography radiologic features in juvenile idiopathic arthritis patients. ( 30531162 )
2018
9
Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy ( 30541234 )
2018
10
Vitamin D deficiency is associated with higher disease activity and the risk for uveitis in juvenile idiopathic arthritis - data from a German inception cohort. ( 30545399 )
2018
11
Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. ( 30547812 )
2018
12
Features distinguishing juvenile idiopathic arthritis among children with musculoskeletal complaints. ( 30498888 )
2018
13
Disease activity, treatment and long-term prognosis of adult juvenile idiopathic arthritis patients compared with rheumatoid arthritis patients. ( 30499364 )
2018
14
Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis - single-centre experience. ( 30505008 )
2018
15
Correction to: Diffusion-weighted imaging for assessment of synovial inflammation in juvenile idiopathic arthritis: a promising imaging biomarker as an alternative to gadolinium-based contrast agents. ( 30506215 )
2018
16
A case of moderate haemophilia A with inhibitor, carrying the p.R1800H mutation, complicated with juvenile idiopathic arthritis. ( 30507053 )
2018
17
Enrollment Completed for Largest New Onset Cohort Study in Juvenile Idiopathic Arthritis (JIA) History. ( 30508154 )
2018
18
Association between interleukin-10 polymorphisms and juvenile idiopathic arthritis: a meta-analysis. ( 30511559 )
2018
19
Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials. ( 30514320 )
2018
20
The effects of 8-week water-running program on exercise capacity in children with juvenile idiopathic arthritis: a controlled trial. ( 30430201 )
2018
21
Methotrexate-Induced Vasculitis in a Child with Systemic Onset Juvenile Idiopathic Arthritis. ( 30431484 )
2018
22
Comparison of Different Diagnostic Guidelines for the Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: Single Centre Experience. ( 30431724 )
2018
23
A Comparison of Radiographic Joint Space Width Measurements Versus Ultrasonographic Assessment of Cartilage Thickness in Children with Juvenile Idiopathic Arthritis. ( 30442828 )
2018
24
The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study. ( 30448935 )
2018
25
Hospital clinical pathways for children affected by juvenile idiopathic arthritis. ( 30458837 )
2018
26
Feasibility of a musculoskeletal ultrasound intervention to improve adherence in juvenile idiopathic arthritis: a proof-of concept trial. ( 30466449 )
2018
27
Physical Fitness in Patients with Oligo- and Polyarticular Juvenile Idiopathic Arthritis Diagnosed in the Era of Biologics - A Controlled Cross-Sectional Study. ( 30474929 )
2018
28
No preventive or therapeutic efficacy of infliximab against macrophage activation syndrome due to systemic juvenile idiopathic arthritis. ( 30406708 )
2018
29
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis. ( 30406853 )
2018
30
Self-management needs of Irish adolescents with Juvenile Idiopathic Arthritis (JIA): how can a Canadian web-based programme meet these needs? ( 30409209 )
2018
31
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. ( 30411654 )
2018
32
The association between TNF-α 238A/G and 308A/G polymorphisms and juvenile idiopathic arthritis: An updated PRISMA-compliant meta-analysis. ( 30412082 )
2018
33
Surveillance of adverse drug events associated with etanercept prescribed for juvenile idiopathic arthritis in a single center up to 9-years: A retrospective observational study. ( 30412634 )
2018
34
Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children. ( 30413164 )
2018
35
Juvenile idiopathic arthritis flare due to rice bodies in the knee of a 10-year-old girl. ( 30421710 )
2018
36
A Granulocyte-Specific Protein S100A12 as a Potential Prognostic Factor Affecting Aggressiveness of Therapy in Patients with Juvenile Idiopathic Arthritis. ( 30426025 )
2018
37
Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. ( 30427514 )
2018
38
Specific Sport Habits, Leisure-Time and School-Educational Physical Activity in Children with Juvenile Idiopathic Arthritis - Patterns and Barriers. ( 30354015 )
2018
39
Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. ( 30358861 )
2018
40
Czech Dysplasia Masquerading as Juvenile Idiopathic Arthritis. ( 30363003 )
2018
41
Association of Increased Sun Exposure Over the Life-course with a Reduced Risk of Juvenile Idiopathic Arthritis. ( 30378692 )
2018
42
Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis. ( 30396593 )
2018
43
Correction to: Inter- and intra-observer reliability of contrast-enhanced magnetic resonance imaging parameters in children with suspected juvenile idiopathic arthritis of the hip. ( 30328480 )
2018
44
Physical activity in patients with oligo- and polyarticular juvenile idiopathic arthritis diagnosed in the era of biologics: a controlled cross-sectional study. ( 30333025 )
2018
45
Foxp3 Molecular Dynamics in Treg in Juvenile Idiopathic Arthritis. ( 30333832 )
2018
46
Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. ( 30336181 )
2018
47
Juvenile idiopathic arthritis at school: who understands? ( 30336891 )
2018
48
Transition from child to adult care in an outpatient clinic for adolescents with juvenile idiopathic arthritis: An inductive qualitative study. ( 30338100 )
2018
49
Height and sexual maturation in girls with juvenile idiopathic arthritis. ( 30339783 )
2018
50
Transient natural killer cell dysfunction associated with interleukin-18 overproduction in systemic juvenile idiopathic arthritis. ( 30345698 )
2018

Variations for Juvenile Rheumatoid Arthritis

Expression for Juvenile Rheumatoid Arthritis

Search GEO for disease gene expression data for Juvenile Rheumatoid Arthritis.

Pathways for Juvenile Rheumatoid Arthritis

Pathways related to Juvenile Rheumatoid Arthritis according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630

Pathways related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B
2
Show member pathways
13.7 IL18 IL1B IL1R1 IL1RN IL2RA IL6
3
Show member pathways
13.57 IL18 IL1B IL1R1 IL2RA IL6 LTA
4
Show member pathways
13.44 IL18 IL1B IL1R1 IL2RA IL6 LTA
5
Show member pathways
13.34 IL18 IL1B IL1R1 IL2RA IL6 LTA
6
Show member pathways
13.29 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL1R1
7
Show member pathways
12.8 IL2RA IL6 LTA TNF TNFRSF1B
8
Show member pathways
12.8 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL2RA
9
Show member pathways
12.79 IL18 IL1B IL6 S100A12 TNF
10
Show member pathways
12.76 IL1B IL1R1 IL6 LTA TNF TNFRSF1B
11
Show member pathways
12.76 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL2RA
12
Show member pathways
12.71 IL1B IL1R1 LTA TNF TNFRSF1B
13
Show member pathways
12.67 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL2RA TNF
14
Show member pathways
12.65 IL1B IL1R1 LTA TNF TNFRSF1B
15 12.6 IL1B IL1RN IL2RA TNF TNFRSF1B
16
Show member pathways
12.45 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL1R1
17 12.38 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1R1 IL2RA IL6
18
Show member pathways
12.36 CRP IL1B IL6 TNF
19
Show member pathways
12.36 IL1B IL6 S100A9 TNF
20 12.35 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL6 TNF
21
Show member pathways
12.33 IL1B IL1R1 IL6 TNF
22
Show member pathways
12.32 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1B TNF
23
Show member pathways
12.32 IL18 IL1B IL2RA IL6 LTA TNF
24 12.27 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL6
25
Show member pathways
12.26 IL18 IL1B IL1R1 IL1RN IL6 TNF
26
Show member pathways
12.22 IL1B IL1R1 IL6 TNF
27 12.21 IL1B IL1RN IL6 TNF
28
Show member pathways
12.13 IL18 IL1B IL1R1 IL2RA IL6 TNFRSF1B
29
Show member pathways
12.1 IL18 IL1B IL1R1 IL6 LTA TNF
30 12.06 IL1B IL1R1 IL6 TNF
31 12.06 IL18 IL1B IL6 TNF TNFRSF1B
32
Show member pathways
12.05 HLA-DRB1 IL18 IL1B IL1R1 IL2RA
33 12.03 IL1B IL6 LTA TNF TNFRSF1B
34 11.95 IL1B IL1R1 IL6 TNF
35 11.94 IL1B IL1R1 LTA TNF
36 11.91 IL1B IL6 TNF
37 11.85 IL18 IL1B IL6
38 11.81 IL18 IL1B IL1R1 IL2RA LTA TNF
39 11.79 IL1B IL6 TNF
40 11.78 IL1B IL6 TNF
41 11.77 IL18 IL1B IL1RN IL6 TNF
42 11.7 IL1B IL6 TNF
43
Show member pathways
11.69 IL1B IL6 TNF
44 11.67 IL18 IL1B IL6 TNF
45 11.66 IL1R1 LTA TNF TNFRSF1B
46 11.65 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL18 IL1B IL6
47 11.63 HLA-DPB1 HLA-DQA1 HLA-DRB1
48 11.61 IL18 IL1B IL6 TNF
49
Show member pathways
11.58 LTA TNF TNFRSF1B
50 11.57 BGLAP IL1B IL6 TNF

GO Terms for Juvenile Rheumatoid Arthritis

Cellular components related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 BGLAP CRP IL18 IL1B IL1RN IL6
2 endosome membrane GO:0010008 9.78 HLA-DPB1 HLA-DQA1 HLA-DRB1 SLC11A1
3 lysosome GO:0005764 9.77 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1B SLC11A1
4 trans-Golgi network membrane GO:0032588 9.69 HLA-DPB1 HLA-DQA1 HLA-DRB1
5 endocytic vesicle membrane GO:0030666 9.63 HLA-DPB1 HLA-DQA1 HLA-DRB1
6 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 transport vesicle membrane GO:0030658 9.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
8 extracellular region GO:0005576 9.44 BGLAP CRP HAPLN1 IL18 IL1B IL1R1
9 clathrin-coated endocytic vesicle membrane GO:0030669 9.43 HLA-DPB1 HLA-DQA1 HLA-DRB1
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DPB1 HLA-DQA1 HLA-DRB1
11 MHC class II protein complex GO:0042613 9.13 HLA-DPB1 HLA-DQA1 HLA-DRB1
12 plasma membrane GO:0005886 10.27 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1R1 IL1RN IL2RA

Biological processes related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 IL1B IL1RN S100A12 TNF
2 response to lipopolysaccharide GO:0032496 9.95 IL1B LTA SLC11A1 TNFRSF1B
3 cellular response to lipopolysaccharide GO:0071222 9.92 IL1B IL1RN IL6 TNF TNFRSF1B
4 cytokine-mediated signaling pathway GO:0019221 9.92 IL18 IL1B IL1R1 IL1RN IL2RA IL6
5 defense response to Gram-positive bacterium GO:0050830 9.9 CRP IL6 LTA TNF
6 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.89 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 positive regulation of JNK cascade GO:0046330 9.89 IL1B IL1RN TNF
8 neutrophil chemotaxis GO:0030593 9.88 IL1B IL1RN S100A12 S100A9
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL18 IL1B IL6 S100A12 S100A9 TNF
10 cellular response to organic cyclic compound GO:0071407 9.87 IL18 IL1B TNF
11 interferon-gamma-mediated signaling pathway GO:0060333 9.87 HLA-DPB1 HLA-DQA1 HLA-DRB1
12 regulation of inflammatory response GO:0050727 9.87 IL1R1 S100A9 TNF
13 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 LTA TNF TNFRSF1B
14 positive regulation of inflammatory response GO:0050729 9.87 IL18 S100A12 S100A9 TNF
15 humoral immune response GO:0006959 9.85 IL6 LTA TNF
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 IL18 IL6 TNF
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL18 IL1B TNF
18 interleukin-1-mediated signaling pathway GO:0070498 9.84 IL1B IL1R1 IL1RN
19 positive regulation of T cell proliferation GO:0042102 9.84 HLA-DPB1 IL1B IL2RA IL6
20 response to glucocorticoid GO:0051384 9.83 BGLAP IL1B IL1RN IL6 TNF
21 antigen processing and presentation GO:0019882 9.82 HLA-DPB1 HLA-DQA1 HLA-DRB1
22 positive regulation of JUN kinase activity GO:0043507 9.81 IL1B IL1RN TNF
23 positive regulation of interleukin-6 production GO:0032755 9.81 IL1B IL1RN IL6 TNF
24 positive regulation of phagocytosis GO:0050766 9.8 IL1B SLC11A1 TNF
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 IL18 IL1B TNF
26 negative regulation of neurogenesis GO:0050768 9.78 IL1B IL6 TNF
27 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 IL1B TNF TNFRSF1B
28 negative regulation of growth of symbiont in host GO:0044130 9.72 LTA TNF
29 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL1B TNF
30 regulation of osteoclast differentiation GO:0045670 9.72 BGLAP TNF
31 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.72 HLA-DPB1 HLA-DQA1 HLA-DRB1
32 inflammatory response to antigenic stimulus GO:0002437 9.71 HLA-DRB1 IL2RA
33 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.71 IL18 IL1B
34 T-helper 1 type immune response GO:0042088 9.71 HLA-DRB1 IL18
35 positive regulation of interferon-gamma production GO:0032729 9.7 HLA-DPB1 IL18 IL1B IL1R1 LTA SLC11A1
36 inflammatory response GO:0006954 9.7 CRP IL18 IL1B IL1R1 IL1RN IL6
37 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IL1B TNF
38 interleukin-6 production GO:0032635 9.68 IL18 IL1B
39 negative regulation of glutamate secretion GO:0014050 9.68 IL1B IL1RN
40 regulation of establishment of endothelial barrier GO:1903140 9.68 IL1B TNF
41 negative regulation of lipid storage GO:0010888 9.67 CRP IL6 TNF
42 positive regulation of glial cell proliferation GO:0060252 9.67 IL1B IL6 LTA TNF
43 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.66 IL1RN IL6
44 positive regulation of fever generation GO:0031622 9.65 IL1B TNF
45 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 LTA TNF
46 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.65 IL18 IL1B IL1R1
47 sequestering of triglyceride GO:0030730 9.64 IL1B TNF
48 chronic inflammatory response to antigenic stimulus GO:0002439 9.63 IL1B IL1RN TNF
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 IL1B TNF
50 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.61 LTA TNF

Molecular functions related to Juvenile Rheumatoid Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.32 IL1B IL1RN
2 MHC class II receptor activity GO:0032395 9.26 HLA-DQA1 HLA-DRB1
3 RAGE receptor binding GO:0050786 9.16 S100A12 S100A9
4 peptide antigen binding GO:0042605 9.13 HLA-DPB1 HLA-DQA1 HLA-DRB1
5 cytokine activity GO:0005125 9.1 IL18 IL1B IL1RN IL6 LTA TNF

Sources for Juvenile Rheumatoid Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....